Skip to main content

Table 4 Treatment-related adverse events

From: A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed

Frequency n (%) Alectinib
(n = 43)
Ceritinib
(n = 22)
Any Grade Grade 3–5 Any Grade Grade 3–5
 Nausea 4 (9.3) 1 (2.3) 6 (27.3) 2 (9.1)
 Diarrhea 2 (4.7) 0 8 (36.4) 3 (13.6)
 Vomiting 3 (6.9) 0 4 (18.2) 1 (4.5)
 Elevation of AST/ALT 10 (23.3) 3 (6.9) 3 (13.6) 1 (4.5)
 Peripheral edema 2 (4.7) 0 2 (9.1) 0
 Blurred vision 1 (2.3) 0 0 0
 Myalgia 5 (11.6) 1 (2.3) 0 0
 Dose reduction 3 (6.9) 5 (22.7)
 Treatment discontinuation 1 (2.3) 0
  1. AST aspartate transaminase; ALT alanine transaminase